Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 4:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Impaired Fasting Glucose Clear all
Completed Phase 4 Interventional

Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy

NCT01239004
View directory record Official record
Conditions
Dyslipidemia, Hyperlipidemia, Hyperglycemia
Interventions
Placebo, Colesevelam
Drug
Lead sponsor
Radiant Research
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Chicago, Illinois • Kansas City, Kansas • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2012 · Synced Sep 21, 2026, 4:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Metformin and Muscle in Insulin-resistant Older Veterans

NCT01804049
View directory record Official record
Conditions
Prediabetes
Interventions
metformin, placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
65 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Sep 21, 2026, 4:23 AM EDT
Completed Phase 4 Interventional Results available

The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose

NCT00673790
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol with concomitant losartan or lisinopril, HCTZ with concomitant losartan or lisinopril, Placebo with concomitant losartan or lisinopril
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 80 Years
Enrollment
537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
88
States / cities
Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Sep 21, 2026, 4:23 AM EDT
Completed Not applicable Interventional Results available

Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass

NCT00775684
View directory record Official record
Conditions
Pre-diabetes, Type 2 Diabetes
Interventions
Exenatide, Sitagliptin, Glimepiride
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
3
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Sep 21, 2026, 4:23 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Pioglitazone on Bone Metabolism in Postmenopausal Women With Impaired Fasting Glucose.

NCT00708175
View directory record Official record
Conditions
Bone Metabolism
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
Up to 70 Years · Female only
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
34
States / cities
Greenbrae, California • Los Banos, California • San Diego, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Sep 21, 2026, 4:23 AM EDT
Completed Not applicable Interventional Results available

Effect of Dietary Glycemic Index on Beta-cell Function

NCT01386645
View directory record Official record
Conditions
Impaired Glucose Tolerance, Oxidative Stress, Prediabetes, Impaired Fasting Glucose
Interventions
low glycemic index (LGI) diet, high glycemic index (HGI) diet plus placebo (PLAC), high glycemic index diet plus N-acetylcysteine
Other · Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Sep 21, 2026, 4:23 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Effects of Vildagliptin on the Insulin Response to Glucose in Subjects With Pre-diabetes

NCT00312130
View directory record Official record
Conditions
Pre-diabetes
Interventions
Vildagliptin
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Sep 21, 2026, 4:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of Psyllium and Microcrystalline Cellulose on Glycemic Measures in Subjects With Impaired Fasting Glucose

NCT01549600
View directory record Official record
Conditions
Impaired Fasting Glucose
Interventions
psyllium, Microcrystalline Cellulose
Dietary Supplement
Lead sponsor
Procter and Gamble
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 27, 2014 · Synced Sep 21, 2026, 4:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome

NCT02948569
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
3-V Bioscience-2640
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
35 Years to 60 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 21, 2026, 4:23 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

The Role of Islet GLP-1 in the Pathogenesis of Prediabetes

NCT06967558
View directory record Official record
Conditions
PreDiabetes
Interventions
Exendin 9-39, Saline
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 21, 2026, 4:23 AM EDT
Terminated Phase 3 Interventional

Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes

NCT00325650
View directory record Official record
Conditions
Prediabetic State
Interventions
Rimonabant, Placebo (for Rimonabant)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
35 Years to 75 Years
Enrollment
2,420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Sep 21, 2026, 4:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of an Intermittent Fasting and Dietary Supplement Regimen on Glycemic Variability

NCT05493553
View directory record Official record
Conditions
Healthy, Impaired Glucose Tolerance
Interventions
Dietary supplement regimen, Dietary supplement and intermittent fasting regimen
Dietary Supplement · Other
Lead sponsor
Unicity International, Inc.
Industry
Eligibility
30 Years to 69 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Sep 21, 2026, 4:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Lantus in Prediabetes

NCT00348972
View directory record Official record
Conditions
Hyperglycemia, Diabetes Mellitus
Interventions
Lantus® (insulin glargine)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2002
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 5, 2006 · Synced Sep 21, 2026, 4:23 AM EDT
Terminated Phase 4 Interventional Results available

Renin-Angiotensin and Fibrinolysis in Humans: Effect of Long-Term PDE5 Inhibition on Glucose Homeostasis

NCT01409993
View directory record Official record
Conditions
Impaired Glucose Tolerance
Interventions
Sildenafil, Placebo, Hyperglycemic clamp, Euglycemic clamp
Drug · Diagnostic Test
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced Sep 21, 2026, 4:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy

NCT01488279
View directory record Official record
Conditions
Pre-diabetes, Impaired Fasting Glucose, Impaired Glucose Tolerance
Interventions
Dexamethasone 2.5 mg and Sitagliptin 100 mg, Dexamethasone 2.5 mg and placebo tablet
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
South Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 11, 2018 · Synced Sep 21, 2026, 4:23 AM EDT
Completed Phase 2 Interventional

Chromium Effects on Insulin and Vascular Function in People at Risk for Diabetes

NCT00067626
View directory record Official record
Conditions
Obesity, Pre-diabetes, Insulin Resistance, Impaired Glucose Tolerance, Impaired Fasting Glucose
Interventions
Chromium
Dietary Supplement
Lead sponsor
Griffin Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Derby, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 14, 2010 · Synced Sep 21, 2026, 4:23 AM EDT
Completed Phase 4 Interventional Results available

Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM

NCT01856907
View directory record Official record
Conditions
Disorder of Glucose Regulation
Interventions
Sitagliptin-Metformin, Metformin, Placebo pill
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 21, 2026, 4:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Lowering Impaired Fasting Glucose Levels With Exercise

NCT03019510
View directory record Official record
Conditions
Type2 Diabetes
Interventions
No exercise, Morning exercise, Evening exercise
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
25 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Sep 21, 2026, 4:23 AM EDT
Completed Phase 4 Interventional Results available

Incretins in Impaired Fasting Glucose

NCT00364377
View directory record Official record
Conditions
Pre-diabetes
Interventions
Sitagliptin, Placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 5, 2011 · Synced Sep 21, 2026, 4:23 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)

NCT01234649
View directory record Official record
Conditions
Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome, Impaired Glucose Tolerance, Disorder of Glucose Regulation
Interventions
Metformin XR plus placebo, Metformin XR plus liraglutide
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Sep 21, 2026, 4:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Incretin Effect in People With Impaired Fasting Glucose

NCT00795275
View directory record Official record
Conditions
Obesity
Interventions
Sitagliptin Phosphate
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
45 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 4, 2021 · Synced Sep 21, 2026, 4:23 AM EDT
Withdrawn Not applicable Interventional

Personalized Smartphone-assisted Coaching System to Improve Glucose Homeostasis in Adults With Prediabetes - Main Study

NCT03315663
View directory record Official record
Conditions
Prediabetes, Hyperglycemia, Postprandial Hyperglycemia, Impaired Glucose Tolerance, Impaired Fasting Glucose
Interventions
Sweetch App & DBWS, Sweetch App Alone
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Baltimore, Maryland • Reading, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Sep 21, 2026, 4:23 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Enhancing Fitness in Older Pre-diabetic Veterans

NCT00594399
View directory record Official record
Conditions
Impaired Glucose Tolerance, Obesity, Diabetes
Interventions
Physical Activity Counseling
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
60 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 26, 2015 · Synced Sep 21, 2026, 4:23 AM EDT
Completed Not applicable Interventional Results available

D Vitamin Intervention in VA

NCT01375660
View directory record Official record
Conditions
Impaired Fasting Glucose, Impaired Glucose Tolerance, Vitamin D Insufficiency
Interventions
Placebo, 50K vitamin D2
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
35 Years to 85 Years · Male only
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 21, 2026, 4:23 AM EDT